ReviewFrontiers in cardiovascular medicine2023

A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™.

Patrick L Iversen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.